'Essentially witchcraft:' A former naturopath takes on the field

ErosDervishiforSTATBrittHermesonceconsideredherselfadoctor.Now,she’sanapostate.Hermesspentthreeyears PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year




knowledge

author：leisure time    Page View：39
Alastair Grant/AP

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met. 

advertisement

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline. 

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Study: Why relieving medical debt did not improve financial outcomes
Next article： George Santos makes 1st court appearance after pleading not guilty to 13 counts